

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ping HUANG et al.
Title: PHOSPHATE MIMICS AND METHODS OF TREATMENT USING
PHOSPHATEASE INHIBITORS
Prior Appl. No.: 09/645,879
Prior Appl. Filing Date: 08/25/2000
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/645,879, filed 08/25/2000. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

July 14, 2003

By

Beth A. Burrous

FOLEY & LARDNER

Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5475

Facsimile: (202) 672-5399

Beth A. Burrous

Attorney for Applicant

Registration No. 35,087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: July 11, 2003 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Prior Application Number	09/645,879
				Prior Appl. Filing Dat	08/25/2000
				First Name and Inventor	Ping HUANG
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	038602-1618
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	5,710,173	A	TANG et al.	01-20-1998	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)		
	A2	WO	98/56376	A1	SUGEN, INC.	12-17-1998

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A3	LEE et al., "Antiproliferative activity induced by the somatostatin analogue, TT-232, in human pancreatic cancer cells," PubMed Abstract 12110500, <u>Eur. J. Cancer</u> , July 2002, pp. 1526-1534, Vol. 38, No. 11	
	A4	TSENG et al., "Microtubule damaging agents induce apoptosis in HL 60 cells and G2/M cell cycle arrest in HT 29 cells," PubMed Abstract 12049842, <u>Toxicology</u> , June 14, 2002, pp. 123-142, Vol. 175, No. 1-3	
	A5	UKKOLA et al., "Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities," PubMed Abstract 12028501, <u>J. Intern. Med.</u> , June 2002, pp. 467-475, Vol. 251, No. 6	
	A6	XU et al., "Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms," PubMed Abstract 12134145, <u>Nat. Immuno.</u> , August 2002, pp. 764-771, Vol. 3, No. 8	
	A7	JENKINS et al., "Solid-phase synthesis and biochemical studies of O-boranophosphopeptides and O-dithiophosphopeptid," PubMed Abstract 12047178, <u>J. Am. Chem. Soc.</u> , June 12, 2002, pp. 6584-6593, Vol. 124, No. 23	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450,